113 related articles for article (PubMed ID: 11697437)
1. Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barré syndrome.
Go T
Acta Paediatr; 2001 Oct; 90(10):1202-4. PubMed ID: 11697437
[TBL] [Abstract][Full Text] [Related]
2. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate.
Meythaler JM; Korkor AB; Nanda T; Kumar NA; Fallon M
Arch Intern Med; 1986 Aug; 146(8):1567-71. PubMed ID: 3089187
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of immobilization hypercalcemia using calcitonin and etidronate.
Meythaler JM; Tuel SM; Cross LL
Arch Phys Med Rehabil; 1993 Mar; 74(3):316-9. PubMed ID: 8439262
[TBL] [Abstract][Full Text] [Related]
4. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
Hasling C; Charles P; Mosekilde L
Eur J Clin Invest; 1986 Oct; 16(5):433-7. PubMed ID: 3100312
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV
Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049
[TBL] [Abstract][Full Text] [Related]
6. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry.
Meunier PJ; Chapuy MC; Delmas P; Charhon S; Edouard C; Arlot M
Am J Med; 1987 Feb; 82(2A):71-8. PubMed ID: 3103438
[TBL] [Abstract][Full Text] [Related]
7. Immobilization hypercalcemia in acute spinal cord injury treated with etidronate.
Merli GJ; McElwain GE; Adler AG; Martin JH; Roberts JD; Schnall B; Ditunno JF
Arch Intern Med; 1984 Jun; 144(6):1286-8. PubMed ID: 6428341
[TBL] [Abstract][Full Text] [Related]
8. Intravenous etidronate in the management of malignant hypercalcemia.
Ryzen E; Martodam RR; Troxell M; Benson A; Paterson A; Shepard K; Hicks R
Arch Intern Med; 1985 Mar; 145(3):449-52. PubMed ID: 3919667
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cancer-associated hypercalcemia with mithramycin and oral etidronate disodium.
Shevrin DH; Bressler LR; McGuire WP; Kukreja SC; Kukla LJ; Lad TE
Clin Pharm; 1985; 4(2):204-5. PubMed ID: 2985326
[No Abstract] [Full Text] [Related]
10. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.
Singer FR; Ritch PS; Lad TE; Ringenberg QS; Schiller JH; Recker RR; Ryzen E
Arch Intern Med; 1991 Mar; 151(3):471-6. PubMed ID: 1900410
[TBL] [Abstract][Full Text] [Related]
11. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.
Varache N; Audran M; Clochon P; Lortholary A; Bouachour G; Alquier P; Basle MF
Clin Rheumatol; 1991 Sep; 10(3):328-32. PubMed ID: 1790647
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.
Ringenberg QS; Ritch PS
Clin Ther; 1987; 9(3):318-25. PubMed ID: 3111705
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
Kanis JA; Urwin GH; Gray RE; Beneton MN; McCloskey EV; Hamdy NA; Murray SA
Am J Med; 1987 Feb; 82(2A):55-70. PubMed ID: 3103437
[TBL] [Abstract][Full Text] [Related]
14. Etidronate disodium in the management of malignancy-related hypercalcemia.
Hasling C; Charles P; Mosekilde L
Am J Med; 1987 Feb; 82(2A):51-4. PubMed ID: 3103436
[TBL] [Abstract][Full Text] [Related]
15. Etidronate for hypercalcemia of malignancy and osteoporosis.
Horowitz E; Miller JL; Rose LI
Am Fam Physician; 1991 Jun; 43(6):2155-9. PubMed ID: 1904188
[TBL] [Abstract][Full Text] [Related]
16. Disodium etidronate in hypercalcaemia due to immobilisation.
Hägg E; Eklund M; Tørring O
Br Med J (Clin Res Ed); 1984 Feb; 288(6417):607-8. PubMed ID: 6421398
[No Abstract] [Full Text] [Related]
17. Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
Flores JF; Singer FR; Rude RK
Miner Electrolyte Metab; 1991; 17(6):390-5. PubMed ID: 1823390
[TBL] [Abstract][Full Text] [Related]
18. Contrasting effects of intravenous and oral etidronate on vitamin D metabolism in man.
Lawson-Matthew PJ; Guilland-Cumming DF; Yates AJ; Russell RG; Kanis JA
Clin Sci (Lond); 1988 Jan; 74(1):101-6. PubMed ID: 3123117
[TBL] [Abstract][Full Text] [Related]
19. Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m.
Murphy KJ; Line BR; Malfetano J
Can Assoc Radiol J; 1997 Jun; 48(3):199-202. PubMed ID: 9193420
[TBL] [Abstract][Full Text] [Related]
20. Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia.
Singer FR
Semin Oncol; 1990 Apr; 17(2 Suppl 5):34-9. PubMed ID: 2110387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
